medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2010, Number 4

<< Back Next >>

Arch Neurocien 2010; 15 (4)

Effects of bupropion on depression, anxiety and smoking cessation

Hernández-Lozano M, Gutiérrez-García AG, Contreras CM, Alcántara-López MG

Language: Spanish
References: 64
Page: 260-266
PDF size: 136.43 Kb.


ABSTRACT

Anxiety and affective disorders are the most common psychiatric illness throughout the world and noticeably, recent data reveals a strong correlation between the incidence of anxiety and depression with tobacco smoking. In fact, individuals with affective disorders are more likely to be tobacco smokers. Bupropion is a monocyclic aminoketone (chloropropiophenone) structurally associated to the phenylethylamine family. It exerts antidepressant and anxiolytic properties in preclinical and clinical studies and produces less side effects compared to atypical and selective serotonin reuptake inhibitors. In addition,bupropion is a good auxiliary when attempting to give up smoking and, although further studies are needed, it seems to have shown potential as a treatment for attention-deficit hyperactivity disorder. Its antidepressant, anxiolytic and tobacco cessationactions may involve nonselective reuptake of dopamine and noradrenaline in cortical and some subcortical regions which modulate emotions. However, bupro on could also exert actions over serotonergic system and particularly as cholinergic nicotine receptor antagonist. The aim of this review is to approach the pharmacology of bupropion and a variety of preclinical and clinical research cases that support its use as an antidepressant, anxiolytic and anti-smoking drug.


REFERENCES

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4a. Edición. Washington, DC: American Psychiatric Association 2000; 371.

  2. Lloyd K, Jenkins R. Chronic depression and anxiety in primary care: approaches to liaison. APT 1995;1:192-8.

  3. Ani C, Bazargan M, Hindman D, Bell D, Faroog MA, Akhanjee L, et al. Depression symptomatology and diagnosis: discordance between patients and physicians in primary care settings. BMJ Fam Pract 2008;9:1.

  4. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent, CNS Drug Rev 2006;12(3-4):178-07.

  5. Mykletun A, Overland S, Aaro LE, Liabo HM, Steward R. Smoking in relation to anxiety and depression: evidence from a large population survey: The HUNT study. Eur Psychiatry 2008;23(2): 77-84.

  6. Mansvelder HD, Fagen ZM, Chang B, Mitchum R, McGehee DS. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol 2007;74(8):1283-91.

  7. Gale C, Davidson O. Generalized anxiety disorder. BJM 2007;334(7593):579-81.

  8. Réneric JP, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacol (Berl) 1998;136(2):190-7.

  9. Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001; 62(10):776-81.

  10. David DJP, Renard CE, Jolliet P, Hascoet M, Bourin M. Antidepressant-like effects in various mice strains in the forced swimming test. Psychopharmacology (Berl) 2003:166(4):373-82.

  11. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Couhglin S. A Review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake Inhibitor. Prim Care Companion J Clin Psychiatry 2004;6(4):159-66.

  12. Jefferson JW. Bupropion extended-release for depressive disorders. Expert Rev Neurother 2008;8(5):715-22.

  13. Sigma-Aldrich. Bupropion Hydrochloride (B102). Material safety data sheet. Versión 1.3. Saint Louis MO. Sigma-Aldrich, 2006.

  14. Ferris RM, Cooper BR. Studies of bupropion’s mechanism of antidepressant activity. J Clin Psychiatry 1993; 44(5 Pt 2):74-8.

  15. Musso DL, Mehta NB, Soroko FE, Ferris RM, Hollingsworth EB, Kenney BT. Synthesis and evaluations of the antidepressant activity of the enantiomers of bupropion. Chirality 1993;5(7):495- 500.

  16. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68(7):653-89.

  17. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.

  18. Suckow RF, Smith TM, Perumal AS, Cooper TB. Pharmacokinetics of bupropión and metabolites in plasma and brain of rats, mice and guinea pigs.A fs Drug Metab Dispos 1986;14(6):692-7.

  19. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44 (5 Pt 2):79-81.

  20. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28(10):1176-83.

  21. Nomikos GG, Damsma G, Wenkstem D, Fibiger HC. (1989). Acute effects of bupropion on extracellular dopamine concentrationsin rat striatum and nucleus accumbens studied by in vivo microdyalisis. Neuropsychopharmacology 1989;2(4):273-9.

  22. Li SX, Perry KW, Wong DT. Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 2002;42(2):181-90.

  23. Stern WC, Rogers J, Fang V, Meltzer H. Influence of bupropion HCL (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Life Sci 1979;25 (20):1717-24.

  24. Dong J, Blier P. Modification of norepinephrine and serotonin, but no dopamine, neuron firing by sustained bupropion treatment. Psychopharmacoly (Berl) 2001;155(1):52-7.

  25. Ghanbari R, El Mansari M, Blier P. Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons. J Psychoparharmacol 2008; 21. En prensa.

  26. El Mansari M,Ghambari R, Janssen S, Blier P. Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain. Neuropharmacology 2008;55(7):1191-98.

  27. Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 1997;5(2):107-12.

  28. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 Years of clinical experience with bupropion HCL: from bupropion to bupropion SR to Bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7(3):106-13.

  29. Findlay WA, Van Wyck Fleet J, Smith PG, Butz RF, Hinton ML, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol 1981;21 (2):127-35.

  30. Martin P, Massol J, Colin JN, Lacomblez L, Puech AJ. Antidepressant profile of bupropión and three metabolites in mice. Pharmacopsychiatry 1990;23(4):187- 94.

  31. Ripoll N, David DJ, Dailly E, Hascoet M, Bourin M. Antidepressant like-effects in various mice strains in the tail suspension test. Behav Brain Res 2003; 143(2):193-200.

  32. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215(1):127-34.

  33. Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effect of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004;504(3):207-11.

  34. Redolat R, Gómez MC, Vicens P, Carrasco MC. Bupropion effects on aggressiveness and anxiety in OF1 male mice. Psychopharmacology (Berl) 2005;177(4):418-27.

  35. Tomarken AJ, Dichter GS, Freyd C, Addington S, Shelton RC. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004;78(3):235-41.

  36. Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psichiatry 1991;52(8): 329-35.

  37. Gualtieri CT, Johnson LG. Bupropion normalizes cognitive performance in patients with depression. Med GenMed 2007; 31:9(1):22.

  38. Anderson JM, Greenway FL, Fujioka K, Gadde KM, McKenney J, O’ Neil PM. Bupropion SR enhances weight loss: a 48-week doubleblind, placebo-controlled trial. Obes Res 2002;10(7):633-41.

  39. Robertson B, Wang L, Diaz MT, Aiello M, Gersing K, Beyer J, et al. Effect of bupropion extended release on negative emotion proccesing in major depressive disorder: a pilot functional magnetic resonance imaging study. J Clin Psychiatry 2007;68(2): 261-7.

  40. Carrasco MC, Vicens P, Vidal J, Redolat R. Effects of acute administration of bupropion on behavior in the elevated plusmaze test by NMRI mice. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(7):1135-41.

  41. Nielsen JA, Shannon NJ, Bero L, Moore KE. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav 1986;24(4):795-99.

  42. Contreras CM, Alcalá-Herrera V, Marván ML. Action of antidepressant on the septal nuclei of the rat. Physiol Behav 1989;46(5):793-98.

  43. Treit D, Pesold C, Rotzinger S. Dissociating the anti-fear effects of septal and amigdaloid lesions using two pharmacologically validate models of rat anxiety. Behav Neurosci 1993;107(5):779-85.

  44. Yadin E, Thomas E, Grishkat HL, Strickland CE. The role of the lateral septum in anxiolysis. Physiol Behav 1993;53(6):1077-83.

  45. File SE, Cheeta S, Kenny PJ. Neurobiological mechanisms by which nicotine mediates different types of anxiety. EurJ Pharmacol 2000;393(1-3):231-6.

  46. Zarrindast MR, Homayoun H, Babaie A, Etminani A, Gharib B. Involvement of adrenergic and cholinergic systems in nicotineinduced anxiogenesis in mice. Eur J Pharmacol 2000;407(1- 2):145-58.

  47. Emmanuel NP, Lydiard RB, Ballenger JC.Treatment of social phobia with bupropion. J Clin Psychopharmacol 1991;11(4):276-7.

  48. Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion XL vs escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008;41(1):46-51.

  49. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. J Clin Psychopharmacol 2001:21(1):94-8.

  50. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, et al. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 2000;148(1):33-40.

  51. Rauhut AS, Neugebauer N, Dwoskin LP, Bardo MT. Effect of bupropion on nicotine self-administration in rats. Psychopharmacol (Berl) 2003;169(1):1-9.

  52. Malin DH, Lake JR, Smith TD, Khambati HN, Meyers-Paal RL, Montellano AL, et al. Bupropion attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 2006;184(3- 4):494-503.

  53. Paterson, NE. Behavioural and pharmacological mechanism of bupropion’ s anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol, 2009;603(1-3):1-11.

  54. Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits nicotineevoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H] norepinephrine. J Pharmacol Exp Ther 2002;302(3):1113-22.

  55. Sampablo-Lauro, Carreras JM, Lores L, Quesada M, Coll F, Sánchez-Agudo L. Smoking cessation and bupropion: anxiety and depression as predictors of therapeutic efficacy. Arch Bronconeumol 2002;38(8):351-5.

  56. Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10(10): 1049-56.

  57. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L. Bupropion sustained release in adolescents with comorbid atention deficit/hyperactivity dissorder and depression, J Am Acad Chil Adolesc Psychiatry 2001;40(3):307-14.

  58. Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158(2):282-8.

  59. Glaxo Smith Kline. Información del producto Wellbutrim SR ® (Bupropion hydrochloride) tabletas de liberación sostenida. Grenville: Glaxo Smith Kline Research Triangle Park, 2007.

  60. Jepsen F, Matthews J, Andrews FJ. Sustained release bupropion overdose: an important cause of prolonged symptoms after an overdose. Emerg Med J 2005;20(6):560-1.

  61. Moreno-Caballero B, Castro-Barrio M, Blanco Andrés C. Aquagenic pruritus due to use of bupropion. Aten Primaria 2002;30(10):662-3.

  62. Bailt CR, Lynch CN, Isbister GK. Bupropion poisoning: a case series. Med J Aust 2003;178(2):61-3.

  63. Chan B, Einarson A, Koren G. Effectiveness of bupropion for smoking during pregnancy. J Addic Dis 2005;24:(2):19-23.

  64. Kolber M, Spooner GR, Szafran O. Adverse events with Zyban (bupropion). CMAJ 2003;169(2):103-4.




2020     |     www.medigraphic.com